UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
DR. REDDY'S LABORATORIES S.A. and DR. REDDY'S LABORATORIES, INC.
Petitioners,
v. MONOSOL RX, LLC
Patent Owner.
Patent No. 8,603,514

DECLARATION OF BOZENA MICHNIAK-KOHN, PH.D.



Table of Contents

		Page
I.	Qualifications	2
II.	Scope of Work	3
III.	Overview of the '514 Patent	4
IV.	File History of the '514 Patent	6
V.	Legal Standards	10
VI.	Level of Ordinary Skill and Relevant Time	13
VII.	Claim Construction	14
VIII.	The State of the Art	14
IX.	Asserted References Disclose or Suggest Each of the Features of the '514 Patent	
	A. Brief Overview of the Asserted References	19
	B. Detailed Analysis of the Claims	27
X.	Concluding Statements	44
XI.	Appendix - List Of Exhibits	45

I, Bozena Michniak-Kohn, declare as follows:

I. QUALIFICATIONS

- 1. My name is Bozena Michniak-Kohn. I am a tenured Professor of Pharmaceutics in the Ernest Mario School of Pharmacy at Rutgers-The State University of New Jersey. I have been employed by Rutgers-The State University of New Jersey, initially as a tenured Associate Professor, and finally a full Professor, since 2005. In February 2011, I founded the Center for Dermal Research (CDR) at Rutgers-The State University of New Jersey and have served as the Director of the CDR since that time. In addition, I served all this time as the Director of the Laboratory for Drug Delivery at the NJ Center for Biomaterials, at Rutgers-The State University of New Jersey. I received my Ph.D in Pharmacology from De Montfort University in 1980.
- 2. In 2016 I was appointed to the Board of Directors of the International Pharmaceutical Excipients Council of the Americas Foundation. I have also been a member of the Editorial Board for the Journal of Drug Research and Development since 2014.
- 3. I currently serve as the Academic Chair of the Transdermal section of the Non-Invasive Macromolecule Consortium Working Group of the Catalent Applied Drug Delivery Institute (since 2014) and am a member of the faculty of the National Institute for Pharmaceutical Technology and Education (since 2014).
- 4. I am the recipient of several awards and honors including the award of Fellow status of the American Association of Pharmaceutical Scientists, in July 2008.
- 5. My research interests and experience focus on the optimization of topical, transdermal and transmucosal drug delivery, including sublingual drug delivery as well as the design and development of oral edible and transdermal drug containing polymer films.
- 6. I have authored numerous publications related to drug delivery and formulation including *Drying of biocompatible polymer films loaded with poorly water soluble drugs nano-*



particles via low temperature forced convection, Int. J. Pharm. (2013), 445, 93-103; Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS Class II drug nanoparticles for pharmaceutical applications, J. Pharmaceutics (2012), 423, 4960508; Synthesis and immobilization of microscale drug particles in polymeric films, (2011), Colloids and Surfaces B.: Bionterfaces (2011), 86(1), 181-188; and Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS Class II drug nanoparticles for pharmaceutical applications, J. Pharmaceutics (2012), 423, 4960508.

7. A summary of my education, experience, publications, patents, award and honors is provided in my CV, a copy of which is separately submitted as EX1003.

II. SCOPE OF WORK

- 8. I understand Mylan Technologies, Inc. ("Mylan") has filed a petition for *inter* partes review challenging claims of U.S. Patent No. 8,603,514 ("the '514 patent"). I have reviewed and considered Mylan's IPR petition and the accompanying Declaration of Graham Buckton, Ph.D.. Applying my independent judgment and expertise, and after having independently reviewed and analyzed all of the materials that Dr. Buckton considered, and after having done the additional work of fact checking and considering whether potential counterarguments may exist, I have come to the same conclusions as Dr. Buckton regarding the obviousness of the '514 patent. I agree with the analysis in his declaration as set forth below. For the sake of efficiency, given that I agree with Dr. Buckton's analysis, I have adopted much of the language and organization from his declaration rather than needlessly rewriting passages. The opinions in this declaration are mine.
- 9. I am being compensated at the rate of \$650.00/hour for my time in this matter and I have no financial interest in the outcome.



III. OVERVIEW OF THE '514 PATENT

- 10. The '514 patent is entitled "Uniform Films For Rapid Dissolve [sic] Dosage Form Incorporating Taste-Masking Compositions." The first page of the patent states that an application for the '514 patent (U.S. Application No. 11/775,484, "the '484 application") was filed on July 10, 2007 and claims priority to several applications. The patent states that the '484 application is a continuation-in-part of U.S. Application No. 10/768,809 ("the '809 application). The '809 application is itself a continuation-in-part application of PCT/US02/32594, PCT/US02/32542, and PCT/US02/32575, which were all filed on October 11, 2002. The earliest claimed priority date of the '484 application is October 12, 2001, the filing date of U.S. Provisional Application No. 60/328,868 ("the '868 application").
- I am informed that a federal judge has found that the '514 patent is only entitled to the benefit of U.S. Provisional Application No. 60/414,276 ("the '276 application") filed on September 27, 2002. For the purposes of my declaration and the prior art presented in the grounds herein, however, I have assumed that the applicable date is the earliest priority date claimed in the '514 patent, October 12, 2001. However, the outcome of my opinions does not depend on which of these dates is used.
- 12. The claims of the '514 patent are generally directed to drug delivery film compositions made of water-soluble or water-swellable polymers. Independent claim 62 of the '514 patent recites the following:
 - 62. A drug delivery composition comprising:
 - (i) a cast film comprising a flowable water-soluble or water swellable film-forming matrix comprising one or more substantially water soluble or water swellable polymers; and a desired amount of at least one active;



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

